Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Nov;16(5):529–535. doi: 10.1111/j.1365-2125.1983.tb02211.x

Haemodynamic dose-response effects of i.v. penbutolol in angina pectoris.

B Silke, S P Verma, M Hussain, G I Nelson, R C Okoli, S H Taylor
PMCID: PMC1428053  PMID: 6315039

Abstract

The haemodynamic dose-response effects of intravenous penbutolol, a newer beta-adrenoceptor antagonist with intrinsic sympathomimetic activity but without cardioselectivity, were evaluated in 10 patients with angiographically documented coronary artery disease. Following four logarithmetically cumulative i.v. boluses (0.5-4 mg dosage range) there was a log linear increase in plasma penbutolol concentration; the levels achieved (51 +/- 8 to 219 +/- 19 ng/ml) were in the therapeutic range (12 to 250 ng/ml). Penbutolol resulted in a linear decrease in heart rate (maximum delta HR - 4 beats/min; P less than 0.01); there was a small increase in pulmonary artery occluded pressure which reached its maximum at the lower doses (maximum delta PAOP + 1 mm Hg; P less than 0.01). The resting cardiac output, blood pressure and calculated systemic vascular resistance were unchanged. During 4 min steady-state supine bicycle exercise there was attenuation of exercise cardiac output (delta C.I. - 0.6 1 min-1 m-2; P less than 0.01) and systolic pressor response (delta SBP - 13 mm Hg; P less than 0.01) compared with control observations without change in other measured or derived variables. The haemodynamic profile of penbutolol compared favourably with other beta-adrenoceptor antagonists previously evaluated under similar conditions in patients with ischaemic heart disease. Over the i.v. dose-range evaluated penbutolol attenuated exercise-induced angina with a relatively modest depression of cardiac performance; the small change induced in resting haemodynamic variables may, in part, have been contributed to by the intrinsic sympathomimetic activity of penbutolol.

Full text

PDF
529

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ablad B., Carlsson E., Dahlof C., Ek L. Some aspects of the pharmacology of beta-adrenorecptor blockers. Drugs. 1976;11(Suppl 1):100–111. doi: 10.2165/00003495-197600111-00025. [DOI] [PubMed] [Google Scholar]
  2. Alderman E. L., Coltart D. J., Wettach G. E., Harrison D. C. Coronary artery syndromes after sudden propranolol withdrawal. Ann Intern Med. 1974 Nov;81(5):625–627. doi: 10.7326/0003-4819-81-5-625. [DOI] [PubMed] [Google Scholar]
  3. Baird I. M., Hill H., Ings R. M., Johnson K. I., McEwen J. Dynamic and kinetic comparison of penbutolol and propranolol in healthy volunteers [proceedings]. Br J Clin Pharmacol. 1977 Jun;4(3):386P–386P. doi: 10.1111/j.1365-2125.1977.tb00734.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bernard N., Cuisinaud G., Sassard J. Determination of penbutolol and its hydroxylated metabolite in biological fluids by reversed-phase high-performance liquid chromatography. J Chromatogr. 1982 Mar 12;228:355–361. doi: 10.1016/s0378-4347(00)80454-5. [DOI] [PubMed] [Google Scholar]
  5. Frick M. H., Hartikainen M., Pörsti P. Penbutolol, a new non-selective beta-adrenergic blocking compound in the treatment of hypertension. A comparision with propranolol. Ann Clin Res. 1978 Apr;10(2):105–106. [PubMed] [Google Scholar]
  6. Giudicelli J. F., Richer C., Chauvin M., Idrissi N., Berdeaux A. Comparative beta-adrenoceptor blocking effects and pharmacokinetics of penbutolol and propranolol in man. Br J Clin Pharmacol. 1977 Apr;4(2):135–140. doi: 10.1111/j.1365-2125.1977.tb00684.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hendry W. G., Silke B., Taylor S. H. Haemodynamic dose-response effects of i.v. metoprolol in coronary heart disease. Eur J Clin Pharmacol. 1981;19(5):323–327. doi: 10.1007/BF00544581. [DOI] [PubMed] [Google Scholar]
  8. Kubik M. M., Hanks G. W. Single daily dose penbutolol in the treatment of hypertension: a double blind crossover comparison with propranolol. Eur J Clin Pharmacol. 1980 Jun;17(6):409–413. doi: 10.1007/BF00570156. [DOI] [PubMed] [Google Scholar]
  9. Lochan R., Silke B., Taylor S. H. Speed of onset of pharmacodynamic activity of propranolol, practolol, oxprenolol and metoprolol after intravenous infection in man. Br J Clin Pharmacol. 1981 Nov;12(5):721–724. doi: 10.1111/j.1365-2125.1981.tb01295.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Maroko P. R., Kjekshus J. K., Sobel B. E., Watanabe T., Covell J. W., Ross J., Jr, Braunwald E. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971 Jan;43(1):67–82. doi: 10.1161/01.cir.43.1.67. [DOI] [PubMed] [Google Scholar]
  11. Müller F. O., Hundt H. K., Bromley P. A., Torres J., Vanderbeke O. Single and divided doses of penbutolol. Clin Pharmacol Ther. 1979 May;25(5 Pt 1):528–535. doi: 10.1002/cpt1979255part1528. [DOI] [PubMed] [Google Scholar]
  12. Norris R. M., Clarke E. D., Sammel N. L., Smith W. M., Williams B. Protective effect of propranolol in threatened myocardial infarction. Lancet. 1978 Oct 28;2(8096):907–909. doi: 10.1016/s0140-6736(78)91628-8. [DOI] [PubMed] [Google Scholar]
  13. Nyberg G., Wilhelmsson C., Vedin A. Intrinsic sympathomimetic activity of penbutolol. Eur J Clin Pharmacol. 1979;16(6):381–386. doi: 10.1007/BF00568197. [DOI] [PubMed] [Google Scholar]
  14. Sapru R. P., Sharma P. L. The effect on myocardial contractility of a new beta-adrenergic receptor blocking drug, penbutolol. Br J Clin Pharmacol. 1978 Dec;6(6):515–520. doi: 10.1111/j.1365-2125.1978.tb00875.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sharma P. L., Sapru R. P. Dose-effect relationship and safety of oral administration of penbutolol. A new beta adrenoceptor antagonist in normal subjects. Int J Clin Pharmacol Biopharm. 1978 Mar;16(3):98–101. [PubMed] [Google Scholar]
  16. Silke B., Hilal A., Taylor S. H. Haemodynamic dose-response effects of intravenous oxprenolol in coronary heart disease. J Cardiovasc Pharmacol. 1981 Jul-Aug;3(4):716–727. doi: 10.1097/00005344-198107000-00006. [DOI] [PubMed] [Google Scholar]
  17. Slogoff S., Keats A. S., Ott E. Preoperative propranolol therapy and aortocoronary bypass operation. JAMA. 1978 Sep 29;240(14):1487–1490. [PubMed] [Google Scholar]
  18. Slome R. Withdrawal of propranolol and myocardial infarction. Lancet. 1973 Jan 20;1(7795):156–156. doi: 10.1016/s0140-6736(73)90235-3. [DOI] [PubMed] [Google Scholar]
  19. Svendsen T. L., Hartling O. J., Trap-Jensen J., McNair A., Bliddal J. Adrenergic beta receptor blockade: hemodynamic importance of intrinsic sympathomimetic activity at rest. Clin Pharmacol Ther. 1981 Jun;29(6):711–718. doi: 10.1038/clpt.1981.100. [DOI] [PubMed] [Google Scholar]
  20. Taylor S. H. Measurement of the cardiac output in man. Proc R Soc Med. 1966;59 (Suppl):35–53. [PMC free article] [PubMed] [Google Scholar]
  21. Taylor S. H., Silke B., Ebbutt A., Sutton G. C., Prout B. J., Burley D. M. A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med. 1982 Nov 18;307(21):1293–1301. doi: 10.1056/NEJM198211183072101. [DOI] [PubMed] [Google Scholar]
  22. Taylor S. H., Silke B., Lee P. S. Intravenous beta-blockade in coronary heart disease: is cardioselectivity or intrinsic sympathomimetic activity hemodynamically useful? N Engl J Med. 1982 Mar 18;306(11):631–635. doi: 10.1056/NEJM198203183061102. [DOI] [PubMed] [Google Scholar]
  23. Thadani U., Davidson C., Singleton W., Taylor S. H. Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med. 1979 Apr 5;300(14):750–755. doi: 10.1056/NEJM197904053001402. [DOI] [PubMed] [Google Scholar]
  24. Vallner J. J., Jun H. W., Needham T. E., Stewart J. T., Brown W., Frazer H., Honigberg I. L. Plasma level studies of penbutolol after oral dose in man. J Clin Pharmacol. 1977 Apr;17(4):231–236. doi: 10.1177/009127007701700407. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES